摘要
对197例原发性肝癌、良性肝胆疾病和胃肠道恶性肿瘤病人进行AFP异质体、γ-GTP-Ⅱ、5'-NPD-V、Ⅵ、GPDA及AFP测定.结果:联合检测肿瘤标志物的检出率为98.10%,在AFP<400μg/L组阳性率为96.27%.联合应用二种及三种标志物时,在AFP>400μg/L组,以AFP异质体+GPDA、AFP+GPDA+γ-GTP-Ⅱ的检出率最高,分别为97.61%和100%;在AFP<400μg/L组,以AFP异质体+5'-NPD-V、Ⅵ和AFP异质体+γ-GTP-Ⅱ+5'-NPD-V、Ⅵ检出率最高,分别为93.55%和96.77%.
We tested 104 primary hepatic carcinoma patients, 88 benign liver-biliary disease patients, 5 gastrointestinal malignancies and 51 normal patients, using AFP variant,λ-GTP-Ⅱ, 5'-NPD-V,Ⅵ, GPDA and AFP concurrently.Apart from using AFP to seperate the patients into AFP>400μg/L and AFP<400μg/L groups, the remaining four markers were used as a combined diagnosis for PHC, employing two or three markers respectively.The results showed that combined assays of PHC markers were superior to that just using one marker in the diagnosis of PHC patients.The more markers used, the higher the sensitivity acquired.Such combined sensitivity for PHC was not influenced by the serum AFP concentration.This suggests that it may be helpful in the diagnosis of PHC patients, particularly for those patients without any AFP elevation, and it can also help differentiate the benign liver-billary disease patients from the PHC patients.
关键词
肝肿瘤
甲胎蛋白
肝癌标志物
诊断
primary hepatic carcinoma
AFP variant
γ-glutamyl traspeptidase isoenzyme
5 '-nucleotide phosphodiesterate isoenzyme
flycyproline dipeptedyl aminopeptidase
